Zenas Biopharma Inc Dossier
Qualitative Analysis
Business overview
Zenas BioPharma, Inc. (Nasdaq: ZBIO) is a clinical-stage global biopharmaceutical company dedicated to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients with autoimmune and rare diseases. Headquartered in Waltham, Massachusetts, the company utilizes a disciplined product candidate acquisition approach combined with a hub-and-spoke operational model to identify, acquire, and develop promising candidates globally. Zenas' lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind both CD19 and Fć̱RIIb to inhibit B-cell lineage activity without depleting the cells. This unique mechanism of action is being evaluated across multiple indications, including immunoglobulin G4-related disease (IgG4-RD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), and warm autoimmune hemolytic anemia (wAIHA). Additionally, the company is advancing orelabrutinib, a highly selective, CNS-penetrant, oral Bruton's Tyrosine Kinase (BTK) inhibitor for MS, alongside several earlier-stage programs.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing lead candidate obexelimab through late-stage clinical trials and regulatory filings, including the BLA submission to the FDA and MAA submission to the EMA for IgG4-RD, while preparing for global commercialization.
Expected impact: Establishment of a core immunology franchise and transition from a clinical-stage to a commercial-stage biopharmaceutical company.
Expanding the clinical pipeline beyond obexelimab by advancing newly in-licensed assets, including studying orelabrutinib in global Phase 3 trials for progressive multiple sclerosis and initiating Phase 1 trials for ZB021 and ZB022.
Expected impact: Reduces single-asset risk by building a diversified portfolio of potentially best-in-class autoimmune therapies.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Secured exclusive rights to develop, manufacture, and commercialize orelabrutinib (a CNS-penetrant BTK inhibitor) for multiple sclerosis and other non-oncology indications outside of China and Southeast Asia, as well as two early-development candidates (ZB021 and ZB022).
Terms: Up to $100 million in upfront and near-term expected milestone payments, with potential regulatory and commercial milestones exceeding $2 billion, plus 7 million shares of Zenas common stock issuable upon achievement of a defined milestone.
Provides non-dilutive funding to support the late-stage development and global commercialization of obexelimab across multiple autoimmune indications.
Terms: Up to $300 million in funding, consisting of a $75 million upfront payment and three additional $75 million payments contingent on defined clinical and regulatory milestones (INDIGO success, FDA approval in IgG4-RD, and FDA approval in SLE), in exchange for a 5.5% royalty on worldwide net sales of obexelimab.